Tuesday, Eli Lilly And Co (NYSE:LLY) reported first-quarter revenue of $8.77 billion, up 26% year over year, marginally missing the consensus of $8.92 billion, driven by increases of 16% in volume and 10% due to higher realized prices. The volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio, and Jardiance, partially offset by declines in Trulicity.  Strong demand for the company’s incretin medicines outpaced supply increases.  Also Read: Changing Frugal Eating Habits – How Novo Nordisk/Eli Lilly’s Weight Loss Drugs Reshaping Food Spending. Mounjaro drove higher realized prices in ...